New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
11:55 EDTFE, TMO, RIGL, PPHM, ODPHigh option volume stocks: FE TMO RIGL PPHM ODP
News For FE;TMO;RIGL;PPHM;ODP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
06:22 EDTPPHMEU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
October 22, 2014
11:34 EDTTMOLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
06:41 EDTPPHMWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
06:13 EDTTMOThermo Fisher reports Q3 Life Sciences Solutions revenue $1.07B
Subscribe for More Information
06:12 EDTTMOThermo Fisher reports expanded adjusted margin by 250 basis points in Q3
Subscribe for More Information
06:02 EDTTMOThermo Fisher narrows FY14 adjusted EPS to $6.87-$6.95 from $6.85-$6.97
Subscribe for More Information
06:00 EDTTMOThermo Fisher reports Q3 adjusted EPS $1.71, consensus $1.69
Subscribe for More Information
October 21, 2014
15:35 EDTTMONotable companies reporting before tomorrow's open
Subscribe for More Information
October 20, 2014
09:01 EDTODPOffice Depot stores now accept Apple Pay
Subscribe for More Information
October 17, 2014
14:50 EDTPPHMBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTPPHMSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 16, 2014
10:32 EDTFEFirstEnergy says second nurse diagnosed with Ebola visited employee
Subscribe for More Information
09:32 EDTODPOffice Depot: European restructuring plan includes reduction of 1,100 positions
Subscribe for More Information
October 15, 2014
12:36 EDTPPHMOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTPPHMEbola linked names rise again amid broader market sell-off
Subscribe for More Information
10:49 EDTPPHMHigh option volume stocks
High option volume stocks: SNV FCG TXT MDSO PPHM NTRS CCL RGP LLTC SOCL
09:20 EDTPPHMOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTPPHMPeregrine up 21% after saying will examine drug as potential Ebola treatment
08:15 EDTPPHMPeregrine says data support Phosphatidylserine as potential target in Ebola
Peregrine Pharmaceuticals announced the publication of a peer-reviewed manuscript, to appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions," related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus-infected cells in vitro. Cyril Empig, Ph.D., associate research director at Peregrine Pharmaceuticals, said, "Our goal with this work was to continue exploring the potential of bavituximab in the antiviral arena and in this case, specifically in biodefense applications. With the increased focus on Ebola, there is an opportunity to take advantage of the specificity of bavituximab for Ebola virus and develop therapeutics or treatment regimens that could neutralize the virus. In addition, recently reported genomic sequence variations in EBOV suggest that drugs targeting specific viral non-variant proteins or protein sequences are at risk of failure as a result of virus escape mutations...Given these data, we are developing a plan to explore potential applications of bavituximab and PS-targeting antibodies in the treatment of Ebola."
October 14, 2014
14:21 EDTTMOThermo Fisher confirms review of alleged Kinetica bugs, Reuters reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use